
~~WHAT IS CLAIMED IS:~~CLAIMS

1. A free base crystalline form of Compound 1



(Compound 1), which is substantially free of other forms of Compound 1.

2. The free base crystalline form of claim **1**, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.1, 8.4, 14.1, 16.9, and 19.0 degrees 2θ (± 0.2 degrees 2θ).

3. The free base crystalline form of claim **2**, further characterized by XRPD peaks at 12.4, 15.2, 16.1, 24.4, and 24.7 degrees 2θ (± 0.2 degrees 2θ)

4. The free base crystalline form of claim **1**, characterized by an X-ray powder diffraction pattern substantially in accordance with **FIG. 1**.

5. The free base crystalline form of any one of claims **1** to **4**, further characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at around 216 °C.

6. The free base crystalline form of any one of claims **1** to **4**, further characterized by a melting point onset of about 213 °C as determined by differential scanning calorimetry thermogram (DSC).

7. The free base crystalline form of any one of claims **1** to **4**, further characterized by a DSC substantially in accordance with **FIG. 2**.

8. A pharmaceutical composition comprising the free base crystalline form of Compound 1 according to any one of claims **1** to **7** and at least one pharmaceutically acceptable excipient.

9. An aqueous suspension comprising the free base crystalline form of Compound 1 according to any one of claims **1** to **7** and at least one excipient.

10. The aqueous suspension of claim **9**, wherein the at least one excipient is at least one suspending agent and/or at least one wetting agent.

11. ~~A method for treating an individual suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors, comprising administering to the individual an effective amount~~ Use of a free base crystalline form of Compound 1 according to any one of claims **1** to **7**, the pharmaceutical composition of claim **8**, or the aqueous suspension of any one of claims 9-10, in the preparation of a medicament for treating an individual suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors.

12. The ~~method~~ use of claim **11**, wherein the disease or disorder is an inflammatory disease or disorder.

13. The ~~method~~ use of claim **12**, wherein the disease or disorder is selected from the group consisting of neutropenia, sepsis, septic shock, Alzheimer's disease, multiple sclerosis, stroke, inflammatory bowel disease, age-related macular degeneration, chronic obstructive pulmonary disorder, inflammation associated with burns, lung injury, osteoarthritis, atopic dermatitis, chronic urticaria, ischemia-reperfusion injury, acute respiratory distress syndrome, systemic inflammatory response syndrome, multiple organ dysfunction syndrome, tissue graft rejection, cancer and hyperacute rejection of transplanted organs.

14. The ~~method~~ use of claim **11**, wherein the disease or disorder is a cardiovascular or cerebrovascular disorder.

15. The ~~method~~ use of claim **14**, wherein the disease or disorder is selected from the group consisting of myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, artherosclerosis, traumatic central nervous system injury and ischemic heart disease.

16. The ~~method~~ use of claim **11**, wherein the disease or disorder is an autoimmune disorder.

17. The ~~method~~ use of claim **16**, wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), systemic lupus erythematosus, Guillain-Barre syndrome, pancreatitis, lupus nephritis, lupus glomerulonephritis, psoriasis, immunoglobulin A (IgA) nephropathy, Crohn's disease, vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, immunovasculitis, tissue graft rejection and hyperacute rejection of transplanted organs.

18. The ~~method~~ use of claim **11**, wherein the disease or disorder is a pathologic sequelae associated with the group consisting of insulin-dependent diabetes, mellitus, lupus nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces.

19. The ~~method~~ use of claim **11**, wherein the disease or disorder is selected from the group consisting of anti-neutrophil cytoplasmic antibody associate (ANCA) vasculitis, C3 glomerulopathy, hidradenitis suppurativa, and lupus nephritis.

20. The ~~method~~ use of claim **11**, wherein the disease or disorder is anti-neutrophil cytoplasmic antibody associate (ANCA) vasculitis.

21. The ~~method~~ use of claim **11**, wherein the disease or disorder is granulomatosis with polyangiitis.

22. The ~~method~~ use of claim **11**, wherein the disease or disorder is microscopic polyangiitis.

23. The ~~method~~ use of claim **11**, wherein the disease or disorder is C3 glomerulopathy.

24. The ~~method~~ use of claim **11**, wherein the disease or disorder is hidradenitis suppurativa.

25. The ~~method~~ use of claim **11**, wherein the disease or disorder is lupus nephritis.

26. The ~~method~~ use of any one of claims **11** to **25**, further comprising ~~administering to the individual an effective amount of~~ one or more additional therapeutic agents to be administered to the individual.

27. The ~~method~~ use of claim **26**, wherein the one or more additional therapeutic agent is rituximab.

28. The ~~method~~ use of claim **26**, wherein the one or more additional therapeutic agent is cyclophosphamide.